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A B S T R A C T
Three-dimensional printing (3DP) has the potential to cause a paradigm shift in the manufacture of pharma-
ceuticals, enabling personalised medicines to be produced on-demand. To facilitate integration into healthcare,
non-destructive characterisation techniques are required to ensure ﬁnal product quality. Here, the use of process
analytical technologies (PAT), including near infrared spectroscopy (NIR) and Raman confocal microscopy, were
evaluated on paracetamol-loaded 3D printed cylindrical tablets composed of an acrylic polymer (Eudragit L100-
55). Using a portable NIR spectrometer, a calibration model was developed, which predicted successfully drug
concentration across the range of 4–40% w/w. The model demonstrated excellent linearity (R2= 0.996) and
accuracy (RMSEP=0.63%) and results were conﬁrmed with conventional HPLC analysis. The model main-
tained high accuracy for tablets of a diﬀerent geometry (torus shapes), a diﬀerent formulation type (oral ﬁlms)
and when the polymer was changed from acrylic to cellulosic (hypromellose, HPMC). Raman confocal micro-
scopy showed a homogenous drug distribution, with paracetamol predominantly present in the amorphous form
as a solid dispersion. Overall, this article is the ﬁrst to report the use of a rapid ‘point-and-shoot’ approach as a
non-destructive quality control method, supporting the integration of 3DP for medicine production into clinical
practice.
1. Introduction
Three-dimensional printing (3DP) has been forecast to revolutionise
the pharmaceutical sector, moving away from a ‘one-size-ﬁts-all’
treatment approach towards personalisation. Indeed, 3DP technology
allows medicines to be tailored to the individual needs of each patient,
for example, by modifying the dosage, shape, size and release char-
acteristics, as well as via production of multi-drug combinations
(Alhnan et al., 2016; Awad et al., 2018a,b; Ghosh et al., 2018; Sadia
et al., 2018b; Smith et al., 2018; Trenﬁeld et al., 2018; Verstraete et al.,
2018; Zema et al., 2017).
To date, ﬁve main 3DP technologies have been researched within
pharmaceuticals; binder jet printing (Wang et al., 2006; Yu et al.,
2009a,b), fused deposition modelling (FDM) (Gioumouxouzis et al.,
2018; Goyanes et al., 2014, 2015a, 2018, 2017a, 2016b; Maroni et al.,
2017; Melocchi et al., 2016), semi-solid extrusion (Khaled et al., 2018;
Khaled et al., 2015a,b), selective laser sintering (SLS) (Fina et al.,
2018a,b, 2017) and stereolithography (SLA) (Goyanes et al., 2016a;
Martinez et al., 2017; Muwaﬀak et al., 2017; Wang et al., 2016). All of
the 3DP technologies follow the 3 D’s of 3D printing (Trenﬁeld et al.,
2018); a) design: computer aided design software is used to create the
dosage form; b) develop: the selected drug(s) and polymer(s) are
blended and loaded into the 3D printer and c) dispense: the 3D dosage
form is fabricated, in a layer by layer manner, to meet the design re-
quirements.
Due to the versatile, compact and user-friendly nature of these 3DP
processes, it is likely that this technology could initiate a new era of
digital pharmacy; with medicine design and production occurring di-
rectly at the point of care, such as within hospital and community
pharmacies (Awad et al., 2018a; Lim et al., 2018). A proposed treat-
ment pathway could involve clinical data being sent to a clinician for
review. A medicine could then be designed to meet the patient’s
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therapeutic requirements (in the form of a digital prescription) and sent
to a local 3D printer for dispensing on-demand (Alhnan et al., 2016;
Awad et al., 2018a; Trenﬁeld et al., 2018).
Despite the many well-documented beneﬁts that 3DP could provide,
adoption of this technology for personalised medicine production has
not yet occurred. Indeed, the relative lack of clinical experience, in
conjunction with the unique features of 3DP compared with more es-
tablished manufacturing processes, pose a number of challenges before
it can be widely integrated (Norman et al., 2017). Most notably, these
relate to the matters of quality control (QC) and safety; such as, how
dose veriﬁcation and drug distribution within the 3D printed tablets can
be ensured (Trenﬁeld et al., 2018).
Conventionally, solid oral dosage forms require content uniformity
and dose veriﬁcation testing, typically by using high performance liquid
chromatography (HPLC) or UV spectroscopy assays. Such tests are
performed on samples from a large batch, which is clearly impossible
for a manufacturing process capable of fabricating single tablets. In
addition, the tests are destructive, expensive and require highly skilled
operators and thus would be impractical within a clinical setting. The
best solution would involve utilising a novel, non-destructive tablet
characterisation method to permit real-time batch release at the clinic
(Trenﬁeld et al., 2018). Process analytical technologies (PAT), such as
spectroscopic tools including near infrared (NIR) and Raman spectro-
scopy, have been previously shown to be capable of monitoring tablet
critical quality attributes (CQAs), namely drug content (Meza et al.,
2006; Wartewig and Neubert, 2005), hardness (Blanco and Alcalá,
2006; Blanco et al., 2006), drug distribution (Eksi-Kocak et al., 2018;
Jérez Rozo et al., 2011) and solid state characteristics (Netchacovitch
et al., 2017). In particular, NIR spectroscopy is favourable due to its
rapid speed of analysis (seconds), non-invasive and non-destructive
nature, ability to analyse solid samples and low cost (Luypaert et al.,
2007; Teixeira et al., 2018).
Previous studies have evaluated the use of PAT technologies for
drug quantiﬁcation of two-dimensional (2D) inkjet printed formula-
tions (Edinger et al., 2017; Vakili et al., 2016, 2017). In contrast, to
date, no such research has been performed around using a simple,
‘point-and-shoot’ approach to quantify accurately the dosage within 3D
printed drug products. A key beneﬁt of 3DP lies in its ability to ﬂexibly
change the dosage form geometry, formulation type or excipients de-
pending on the patient’s preferences or therapeutic requirements. In-
deed, several papers have reported the diﬀering eﬀects of dosage form
shape or structure on both drug release (Fina et al., 2018a; Goyanes
et al., 2015c; Martinez et al., 2018; Sadia et al., 2018a; Wang et al.,
2016; Yang et al., 2018) and patient acceptability (Goyanes et al.,
2017b). As such, a user-friendly and rapid technique that accurately
measures dosage irrespective of the formulation design and composi-
tion would be highly advantageous.
Therefore, this study aimed to create a model that could predict
paracetamol concentration in 3D printed tablets, herein termed print-
lets, fabricated using SLS. The applicability of the model to tablets of
diﬀerent geometries (cylindrical and torus shapes), as well as those
composed of diﬀerent excipients (acrylic and cellulosic polymers) and
diﬀerent formulation types (oral ﬁlms) were evaluated. The printlets
were also characterised using Raman confocal microscopy to observe
drug distribution and solid state characteristics within the printlet
structure.
2. Materials and methods
Paracetamol USP grade (Sigma-Aldrich, UK) was used as a model
drug (MW 151.16, aqueous solubility at 37 °C: 21.80 g/L) (He et al.,
2010). Eudragit L100-55, which is a copolymer of methacrylic acid and
ethyl acrylate (1:1 ratio) that dissolves at pH 5.5 and above, was do-
nated by Evonik, UK. Hydroxypropyl methylcellulose (HPMC) Viva-
pharm E5 was acquired from JRS PHARMA, Germany. Candurin® Gold
Sheen was purchased from Azelis, UK.
2.1. 3D printing process
AutoCAD 2014 (Autodesk Inc., USA) was used to design the tem-
plates for the printlets: (cylindrical, 10mm diameter× 3.6 mm height;
torus-shaped, 10mm diameter× 4mm height; and oral ﬁlms,
10mm×10mm×0.5mm). Fig. 1 shows examples of each printlet
design and image after printing. 3D models were exported as a ste-
reolithography (.stl) ﬁle into the 3D printer Sintratec Central software
Version 1.1.13.
For all formulations, 70 g of paracetamol and the required ex-
cipients were blended using a mortar and pestle (Table 1). 3% w/w of
Candurin® Gold Sheen was added to all the formulations to enhance
energy absorption from the laser to allow printability. Powder mixtures
were transferred to a desktop SLS printer (Sintratec Kit, AG, Brugg,
Switzerland) in order to fabricate the printlets. Powder in the reservoir
platform (150mm×150mm×150mm) of the printer was transferred
by a sled to a build platform (150mm×150mm×150mm), creating
a ﬂat and homogeneously distributed layer of powder.
For all Eudragit L100-55 formulations, the chamber temperature
was set to 90 °C, indicating the temperature inside the printer; and the
surface temperature was set to 110 °C, indicating the surface tempera-
ture of the powder bed during printing. For HPMC E5 formulations,
Fig. 1. Printlet designs and printlets of three diﬀerent geometries; cylinder,
torus and ﬁlm. Ruler units= cm.
Table 1
Active and excipient content of printlets (n= 3) used to create NIR calibration
model. *Indicates concentrations used for internal validation.
Paracetamol content (%
w/w)
Eudragit L100-55
content (%w/w)
Candurin gold sheen
content (%w/w)
4 93 3
8 89 3
12* 85 3
16 81 3
20* 77 3
24 73 3
28 69 3
32* 65 3
36 61 3
40 57 3
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these temperatures were set at 115 °C and 135 °C, respectively. The
printing process started with the activation of a 2.3W blue diode laser
(445 nm; laser scanning speed 100mm/s) to sinter the powder on to the
build platform in a speciﬁed pattern based on the .stl ﬁle. After the ﬁrst
layer of the printlet had been created, the reservoir platform moved up,
the build platform moved down, and the sled distributed a thin layer of
powder on top of the powder bed. This process was repeated layer-by-
layer until printing was complete. The printlets were then removed
from the powder bed and the excess powder was brushed oﬀ. Three
printlets were printed at the same time for each formulation.
2.2. Near infrared spectroscopy (NIR) data acquisition
NIR reﬂectance spectra were measured using a portable benchtop
Labspec 5000 near infrared spectrometer (Analytical Spectral Devices,
USA), equipped with three separate holographic diﬀraction gratings
and three separate detectors; a 512-element silicon photo-diode array
for wavelengths between 350–1000 nm, and two TE-cooled InGaAs for
wavelengths between 1000–1800 nm and 1800–2500 nm. Spectra were
collected using an immobilised lab grade 1m ﬁbre optic cable (ﬁbre
core size 200 μm), which interfaced with the NIR equipment (BIF200-
Vis-NIR, Ocean Optics Inc., FL, USA). A Spectralon 99% reﬂective
standard (Labsphere, North Sutton, UK) was used for instrument cali-
bration prior to spectra acquisition. UV–visible-NIR spectra were col-
lected across the 300–2500 nm wavelength region (2200 data points)
totalling 64 scans, which were averaged.
Each printlet was analysed at six diﬀerent points to avoid potential
sampling errors and to reduce the variability caused by diﬀerent surface
eﬀects. Standard printlets were scanned twice on the topside, twice on
the underside and once on each side. Torus shaped printlets and oral
ﬁlms were scanned three times on the topside and three times on the
underside. The ﬁnal spectrum (used to calculate paracetamol content)
was the average of the spectra recorded at the six positions.
2.3. Model development
Seven printlet concentrations (n=3) were selected for calibration
model development (4%, 8%, 16%, 24%, 28%, 36% and 40% w/w),
and three concentrations (n= 3) were used for internal validation
(12%, 20% and 32% w/w). Multivariate data analysis was performed
using MATLAB software version R2017a (The MathWorks, CA, USA)
with the PLS Toolbox version 8.6 (Eigenvector, CA, USA) for data pre-
processing and modelling. Partial least squares (PLS) regression was
performed on the datasets to build calibration models. The models were
internally cross-validated using venetian blinds.
Validation of the NIR calibration model was performed according to
International Conference on Harmonization (ICH) guidance Q2(R1)
(ICH, 2005), and other regulatory guidance from the European Medi-
cines Agency (EMA) (EMA, 2014) and the Food and Drug Administra-
tion (FDA) (FDA, 2015), by assessing model speciﬁcity, linearity (ex-
pressed as correlation coeﬃcient, R2), accuracy (expressed as the root
mean square error of prediction; RMSEP), precision and intermediate
precision (expressed as relative standard deviation; RSD). The pre-
dictive performance of the model was evaluated by scanning an ex-
ternal validation set of Eudragit L100-55 printlets at 12%, 20% and
32% w/w concentrations. To evaluate whether the model would work
when changing printlet geometry and dosage form type, 3D printed
torus shaped printlets and oral ﬁlms were also scanned. Moreover, the
predictive performance of the model in the presence of other excipients
was evaluated by changing the polymer to HPMC E5.
2.4. Determination of drug content
Following NIR analysis, each individual printlet was quantitatively
analysed for drug content using high performance liquid chromato-
graphy (HPLC). Three individual printlets of each formulation were
placed in separate volumetric ﬂasks with deionised water (250mL). For
Eudragit L100-55-based printlets, 3 drops of 5 N NaOH were added to
each ﬂask to increase the pH to enable dissolution. Samples of solution
were then ﬁltered through 0.22 μm ﬁlters (Millipore Ltd., Ireland) and
the concentration of drug determined with HPLC (Hewlett Packard
1050 Series HPLC system, Agilent Technologies, UK). The validated
HPLC assay entailed injecting 20 μL samples for analysis using a mobile
phase, consisting of methanol (15%) and water (85%), through an Ultra
C8 5 μm column, 250× 4.6mm (Restek, USA) maintained at 40 °C. The
mobile phase ﬂow rate was 1mLmin−1 and the eluent was screened at
a wavelength of 247 nm.
2.5. Raman spectroscopy and mapping
Raman mapping was performed to evaluate the distribution of drug
and polymer within the printlets. The underside surface and cross
section of samples (40% w/w) were mounted and focused using a X50
objective on an InVia confocal Raman microscope (Renishaw, UK)
equipped with a 300mW 785 nm HPNIR Renishaw laser. Spectral ar-
rays were acquired with ca. 4500 spectra recorded over a ca.
300 μm×300 μm (X×Y) surface of the sample using a step size of
5 μm in X and Y. A 1200 line grating was used providing spectral re-
solution up to 1 cm−1. Spectra were collected over the range of
1190–1695 nm, with a 2 s exposure time and 2 accumulations.
Processing was performed using Renishaw WiRE software v.3.4
using direct classical least-squares (DCLS) component matching to
paracetamol (amorphous and crystalline, form I) and Eudragit L100-55
reference spectra to generate 2-dimensional false colour maps.
2.6. X-ray powder diﬀraction
X-ray powder diﬀraction patterns of printlets (ground to a ﬁne
powder), formulation blends and pure paracetamol were recorded using
a Rigaku MiniFlex 600 (Rigaku, USA) with a Cu Kα X-ray source
(λ=1.5418 Å) and accompanying software Miniﬂex Guidance version
1.2.01. The intensity and voltage applied were 15mA and 40 kV. The
angular range of data acquisition was 3–40° 2θ, with a step size of 0.02°
at a speed of 2° min−1.
3. Results and discussion
To facilitate the integration of 3DP into pharmacy practice, the
development of rapid, non-destructive quality control techniques that
permit real time batch release are required. A relatively new 3DP
technology to pharmaceuticals is SLS printing which, to date, has been
used to manufacture a range of dosage forms, including immediate and
controlled release tablets (Fina et al., 2017, 2018a), as well as fast
disintegrating oro-dispersible tablets (Fina et al., 2018b). In the present
study, for the ﬁrst time the manufacture of standard cylindrical and
novel torus-shaped printlets, as well as 3D printed oral ﬁlms, containing
a high drug loading (up to 40% w/w) were successfully produced
(Fig. 1). Paracetamol and Eudragit L100-55 were selected as the model
drug and excipient for calibration development.
3.1. Drug distribution and solid state analysis
To ensure paracetamol was homogenously distributed within the
printlets, Raman confocal microscopy was used which is a non-de-
structive method commonly employed to evaluate drug distribution, as
well as the amorphous and crystalline content, of pharmaceutical ta-
blets and ﬁlms (Goyanes et al., 2015d; Netchacovitch et al., 2017;
Scoutaris et al., 2014). Within this study, a 300 μm×300 μm sized
section on the external underside surface and internal cross section of a
printlet (40% w/w) was scanned using a Raman microscope. At each
point of the formulation mapped, reference paracetamol (amorphous
and crystalline; form I) and Eudragit L100-55 spectra were inputted
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into the software and compared with the printlet spectra collected using
DCLS.
Paracetamol was homogenously distributed across the internal
structure and surface of the printlet (Fig. 2A and 3A). In particular, the
underside surface of the printlet consisted of paracetamol that was
mostly present in the amorphous phase (Fig. 2A; red areas). It was
found that the distribution of the polymer (Eudragit L100-55) pre-
dominantly overlaps with amorphous paracetamol, suggesting that in
these areas paracetamol was present as a solid dispersion (Fig. 2B).
Similar results have also been reported elsewhere (Fina et al., 2017).
There is special interest in delivering drugs as solid dispersions as a
strategy to enhance drug dissolution and bioavailability, particularly
for drugs with inherently low solubility (e.g. BCS Class II or IV com-
pounds) (Capretto et al., 2017; Martínez et al., 2014). As well as SLS,
other thermal 3DP methods have shown the capability of formulating a
variety of drugs as amorphous or semi-amorphous systems
(Kollamaram et al., 2018; Sadia et al., 2016). Within the SLS printing
process, it is likely that the application of heat and laser results in
complete drug melting to enable formation of a non-crystalline matrix.
This process would diﬀer based on the drug, excipients and printing
parameters (e.g. laser scanning speed, chamber temperature) selected.
Areas of crystalline paracetamol form I (green areas) were also
present (Fig. 2A). The areas of crystalline material were attributed to
the presence of residual unsintered powder on the surface of the tablet
that had not been eﬀectively cleared away after printing. To conﬁrm
this, a cross section of the same printlet was taken and the internal
structure was viewed using the Raman microscope. Fig. 3A and B show
that paracetamol was entirely present in the amorphous phase, which
was distributed amongst the Eudragit L100-55 matrix as a solid dis-
persion. This conﬁrms that the amorphous material was not re-crys-
tallising out of the matrix and is instead likely due to remaining un-
sintered powder on the surface. Excess powder remaining on the surface
or trapped inside the pores of SLS printed objects has previously been
reported (Bose et al., 2013; Williams et al., 2005).
To verify the Raman microscopy ﬁndings, XRPD data were collected
for both the powder blends and the standard printlets (Fig. 4). For the
20% and 40% w/w drug-loaded powder blends, characteristic para-
cetamol form I peaks can be observed although these were not observed
at the 4% concentration. It is likely that, while paracetamol would be
present in the crystalline form at 4% w/w, it would be below the de-
tection limit of XRPD analysis. For the printed formulations, the 20%
w/w concentration showed complete conversion of paracetamol into
the amorphous form, conﬁrming that the drug was dispersed into the
polymer matrix. At 40% w/w, it can be seen that the majority of
paracetamol has been converted into the amorphous form (due to peak
height reduction), although several crystalline paracetamol peaks can
be observed. This is most likely attributed to the presence of residual
unsintered powder on the surface of the printlet, which was observed in
the aforementioned Raman maps (Figs. 2 and 3).
Fig. 2. External underside surface of a printlet (40% w/w paracetamol) mapped using Raman confocal microscopy. Red areas= amorphous paracetamol (A), green
areas= crystalline paracetamol (Form I), blue areas= Eudragit L100-55 (B).
Fig. 3. Internal cross section of a printlet (40% w/w paracetamol) mapped using Raman confocal microscopy. Red areas= amorphous paracetamol (A), blue
areas= Eudragit L100-55 (B).
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3.2. Quantitative analysis using NIR
To create a reliable multivariate calibration model, the evaluation
of diﬀerent spectral pre-processing methods was required in order to
extract the relevant chemical information. In this study, a total of ten
PLS models were developed (Table 2); six diﬀerent pre-treatments were
applied to the spectra and for each, two diﬀerent spectral ranges were
evaluated; SR1: 1100–2360 nm and SR2: 1300–2100 nm. For each
model, the correlation coeﬃcient of the calibration curve (R2 Cal) and
the standard error of the calibration curve (RMSEC) were calculated in
order to determine the predictive performance of the model. The cor-
relation coeﬃcient of the test printlets (R2 Pred) and standard error of
the test printlets (RMSEP) were then calculated for the validation set
and the most suitable model was deﬁned as the model with the lowest
RMSEP value with high linearity (i.e. R2 Pred as close to 1 as possible).
In this case, the model selected was model 10, which covered the
1300–2100 nm wavelength range with a 2nd derivative (Sativzky-Golay
method: ﬁlter width of 41 with a 2nd polynomial (Savitzky and Golay,
1964)) and mean-centering pre-processing technique. These pre-treat-
ments are commonly used to improve the accuracy of quantiﬁcation by
enhancing spectral information, reducing baseline drift and reducing
error caused by light scattering eﬀects (Chalus et al., 2005).
The calibration model developed covered a total of 30 samples
(with 7 concentrations being selected for calibration and 3 for valida-
tion) over a paracetamol concentration range of 4–40% w/w. Fig. 5
shows the developed calibration model showing the correlation be-
tween NIR predicted values and the reference concentrations de-
termined with HPLC. Favourably, the model demonstrated excellent
linearity (R2= 0.996), conﬁrming that the NIR test results were pro-
portional to paracetamol concentration in the stated range.
In addition to linearity, further validation of the model was per-
formed by determining several parameters (recommended by ICH (ICH,
2005), FDA (FDA, 2015) and EMA (EMA, 2014) guidelines). These in-
cluded model speciﬁcity, accuracy, precision and intermediate preci-
sion.
3.2.1. Speciﬁcity
For the model to be ﬁt-for-purpose, it must have the ability to
identify explicitly the analyte (i.e. paracetamol) in the presence of the
other components (i.e. Eudragit L100-55 and the colourant). This was
evaluated by comparing the loadings spectra of the 1st latent variable
(LV1), which accounted for 88.8% of the variation in the data, to the
Fig. 4. X-ray powder diﬀraction patterns of pure paracetamol (form I), powder blends (4%, 20% and 40% w/w paracetamol) and printlets (4%, 20% and 40% w/w
paracetamol).
Table 2
Comparison of diﬀerent spectral pre-processing methods and spectral wavelength ranges to develop calibration model. SNV: Standard Normal Variant, D2: Second
derivative spectra (Sativzky-Golay method), MSC: Multiplicative Scatter Correction.
Wavelengths (nm) Model Code Data pre-treatments Latent Variables R2 (Cal) RMSEC (%) R2 (Pred) RMSEP (%)
1100–2360 1 None 2 0.974 2.05 0.956 2.45
2 SNV 2 0.992 1.15 0.985 1.11
3 MSC 3 0.992 1.16 0.985 1.10
4 MSC+D2 2 0.985 1.54 0.957 2.25
5 D2 2 0.990 1.30 0.987 1.25
1300–2100 6 None 3 0.995 0.95 0.990 0.82
7 SNV 2 0.991 1.23 0.969 1.53
8 MSC 2 0.991 1.24 0.970 1.50
9 MSC+D2 2 0.990 1.27 0.986 1.16
10 D2 3 0.996 0.83 0.995 0.63
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reference component spectrum in the 2nd derivative (Fig. 6A and C).
LV1 was found to model well-known paracetamol spectral features at
1625–1675 nm (Traﬀord et al., 1999) and 2000–2050 nm (highlighted
by the red dashed lines on Fig. 6). LV1 was not found to be modelling
the common spectral features of Eudragit L100-55 or Candurin Gold
Sheen (Fig. 6B and 6D). This conﬁrmed that the majority of the var-
iation in the data was caused by the change in paracetamol con-
centration. Un-processed and pre-processed spectra of both the raw
materials and the scanned printlets (4–40% w/w) have been provided
in Supplementary ﬁles Figs. 1 and 2.
Supplementary data associated with this article can be found, in the
online version, at https://doi.org/10.1016/j.ijpharm.2018.08.002.
3.2.2. Accuracy
The accuracy of the calibration model can be expressed as the clo-
seness in agreement between the reference HPLC and the predicted NIR
values (Table 3). ICH Q2 guidance recommends assessing accuracy
using a minimum of nine determinations over a minimum of three
concentration levels (ICH, 2005). As such, standard printlets (n= 3)
from three concentration levels (A: 12%, B: 20% and C: 32% w/w) were
scanned. Table 3 shows the diﬀerence between the HPLC and NIR
predicted paracetamol concentrations. Paired t-test results showed that
there were no signiﬁcant diﬀerences between the HPLC and NIR
methods (p > 0.05) across all three concentrations, conﬁrming that
NIR is a suitable quantiﬁcation method for standard printlets. Com-
pared with HPLC, NIR predictions displayed a slightly higher SD, which
was more evident at lower concentrations. This is likely due to minute
diﬀerences in the surface eﬀects of the printlets. However, this was not
as high for the generally allowed limits of 85–115% required for con-
tent uniformity testing by the MHRA (MHRA, 2018). Accuracy was also
conﬁrmed by having a low error value (RMSEP of 0.63%) and low
prediction bias of −0.26%, which were similar to ﬁndings in the lit-
erature (Traﬀord et al., 1999) (Fig. 5).
One of the main beneﬁts of 3D printing for personalised medicine is
the ability to tailor solid dosage form shape and size, depending on the
patient preference or therapeutic needs (Trenﬁeld et al., 2018). Several
studies have already shown that changing printlet geometry can alter
the dose and drug release characteristics (Goyanes et al., 2015c;
Martinez et al., 2018; Sadia et al., 2018a). It is also well known that NIR
absorbance can be aﬀected by tablet surface eﬀects (Jamrógiewicz,
2012; Saeed et al., 2009) and, as such, it was important to evaluate the
performance of the developed PLS model when scanning printlets of
diﬀerent geometries.
To determine this, torus shaped printlets (12%, 20% and 32% w/w)
and oral ﬁlms with the same formulation composition as the standard
shape were scanned at six diﬀerent points on the formulation. Fig. 7A
and B show that the model predicted the concentrations well, as the
points ﬁtted on the calibration curve. Torus shaped printlets displayed a
slightly higher error compared to oral ﬁlms (RMSEP values of 2.05%
and 1.14%, respectively), which is likely due to the complex rounded
surface structure of this shape, compared with the ﬂat ﬁlms. However,
overall the model continued to be ﬁt-for-purpose for use with diﬀer-
ently shaped tablets of the same composition.
A further beneﬁt of using 3DP for personalised medicine is the
ﬂexibility of changing excipients based on the intended drug release
characteristics. Previous studies have highlighted the eﬀects of diﬀerent
Table 3
Results of dose predicted using the NIR model vs. the reference HPLC method. Target concentrations; A: 12% w/w, B: 20% w/w, C: 32% w/w.
Tablet Test Validation Set
A (% w/w) B (% w/w) C (% w/w)
HPLC NIR HPLC NIR HPLC NIR
1 11.89 11.30 20.38 19.15 32.34 32.94
2 12.07 12.70 19.86 20.15 32.31 32.37
3 11.90 11.19 19.93 19.77 32.61 32.03
Mean ± SD 11.95 ± 0.10 11.73 ± 0.84 20.05 ± 0.28 19.69 ± 0.50 32.42 ± 0.17 32.44 ± 0.46
P value 0.65 (NS) 0.50 (NS) 0.94 (NS)
Fig. 7. PLS models of NIR predicted vs. HPLC determined paracetamol content (% drug load; %DL) of A) ﬁlm shaped printlets and B) torus shaped printlets. Grey
points are calibration (7 concentrations), red points are the test sets (3 concentrations).
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polymer types (Ehtezazi et al., 2018; Fina et al., 2018a; Goyanes et al.,
2015b; Kadry et al., 2018; Kempin et al., 2017; Zhang et al., 2017) and
grades (Goyanes et al., 2017a) on drug dissolution. In the present study,
the calibration model was developed using an acrylate-based polymer
(Eudragit L100-55), however the ability for this model to be applied to
another type of polymer was evaluated. In particular, an external test
set of cylindrical printlets were printed that were composed of HPMC
E5, an immediate release cellulosic polymer, and the predictive per-
formance of the model was evaluated (Fig. 8).
Despite the change in polymer, an excellent predictive performance
was observed (high linearity; R2= 0.984, high accuracy;
RMSEP=1.36%; Fig. 8). Generally, changing the formulation compo-
sition can have varying eﬀects on the model prediction. In this case, Q
residuals and Hotelling T2 scores (Fig. 9) were evaluated which are
statistical tests that can provide a quantitative assessment of anomalous
samples (Li et al., 2010). Both the Q residuals and T2 scores were high
and well exceeded the pre-determined 95% conﬁdence levels,
indicating that the test printlets were not similar to the calibration
printlets and could hence be deemed as ‘outliers’. Despite this, the
model maintained a good predictive performance which is likely due to
the majority of the data variation being attributed to the change in
paracetamol concentration (LV1=88.8%) rather than the polymer.
However, from a regulatory perspective and to ensure model accuracy
in the clinic, it is likely that a calibration model that covers the expected
excipient changes or, alternatively, a separate model for diﬀerent
printlet compositions would have to be devised.
3.2.3. Precision
The precision of the calibration model required evaluation to elu-
cidate the degree of agreement between separate test results upon re-
peated sampling. In the present study, precision was evaluated by
scanning a low dose printlet (6% w/w), in triplicate on each of the six
points, at the same time of day whilst using the same equipment. Six
diﬀerent points were scanned and averaged for each tablet to reduce
the potential spectral variability caused by diﬀering surface eﬀects.
However, this number could be reduced further, for example, by using
larger probes that could scan a bigger region of the tablet surface.
If a 3D printer were to be integrated into pharmacy practice, it is
likely that printlets would be produced at diﬀerent times of day and in
diﬀerent locations. As such, intermediate precision was also evaluated
by performing the same test two weeks later, at a diﬀerent time of day
and in a diﬀerent equipment location. Table 4 shows the results of
precision and intermediate precision. For both tests, the standard de-
viation was low (0.06 and 0.23% w/w, respectively) and was below the
RMSEP value of 0.63%, again demonstrating model accuracy. For
precision and intermediate precision, the relative standard deviation
(RSD) values were also low at< 5% (0.91% and 3.80%, respectively),
demonstrating that the model displays good precision in diﬀerent ex-
perimental conditions. Compared with HPLC, the use of NIR to measure
drug concentration demonstrated a higher SD and RSD, which is not
unexpected due to the known impact of surface eﬀects on NIR spectra.
However, as an alternative method to measure drug concentration in
the clinic, the error demonstrated is low and would be unlikely to be of
clinical signiﬁcance.
Validation of the developed PLS model conﬁrmed that the use of
NIR spectroscopy could provide a feasible alternative to conventional,
destructive dose veriﬁcation methods (e.g. HPLC and UV spectroscopy).
Favourably, the ‘point-and-shoot’ approach developed in the present
study is highly user-friendly and provides a rapid dose prediction with
each tablet scan lasting only ∼10 s. As such, it is likely that the de-
veloped model would be suitable for QC purposes in the clinic. Previous
research has mainly focussed on demonstrating this concept for inkjet
printed pharmaceuticals. For example, Vakili et al. developed a col-
ourimetric quantiﬁcation technique for oral ﬁlms by adding a colourant
to the drug-loaded ink which was scanned using a colourimeter (Vakili
et al., 2016). By increasing the number of layers printed, a greater in-
tensity of colour was detected and, as such, the dose could be quanti-
ﬁed. The same research group also demonstrated the feasibility of using
of a handheld NIR spectrometer to predict levothyroxine and pre-
dnisolone content in inkjet printed oro-dispersible ﬁlms (Vakili et al.,
2017).
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Table 4
Results of precision and intermediate precision experiments using the NIR
model vs. the reference HPLC method.
Scan Precision (%DL) Intermediate
Precision (%DL)
HPLC results (%
DL)
1 6.01 5.67 5.84
2 6.11 6.02 5.82
3 6.02 6.09 5.80
Mean+/−SD (%) 6.05 ± 0.06 5.93 ± 0.23 5.82 ± 0.02
RSD (%) 0.91 3.80 0.34
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The use of NIR chemical imaging (NIR-CI) as a quality control
method for hot melt extruded ﬁlaments and printlets has also been
evaluated (Khorasani et al., 2016). The researchers used multivariate
curve resolution-alternative least squares (MCR-ALS) to predict drug
content. However, in that study a calibration model was not used and,
as such, MCR-ALS could only be classed as a semi-quantitative method.
For a full quantitative characterisation, the development of a calibra-
tion model using partial least squares (PLS) regression is widely used
(Ravn et al., 2008; Roggo et al., 2007) with the FDA and EMA guidance
recognising the use of PLS as a quantitative tool (EMA, 2014; FDA,
2015). As such, it is likely that the developed model in the present study
would be more suitable for QC purposes in the clinic.
Due to the development of small spectroscopic systems, in the fu-
ture, these platforms could be integrated within a 3D printer. This ad-
vancement could overcome the regulatory challenges surrounding the
integration of 3D printing in clinical practice by providing the ability to
both personalise dosage forms and ensure QC within a single step
process.
4. Conclusion
3DP is forecast to transition the manufacture of medicines away
from a ‘one-size-ﬁts-all’ approach towards personalisation. To facilitate
integration of 3DP into clinical pharmacy practice, the evaluation of
non-destructive dose veriﬁcation and characterisation techniques are
required to ensure ﬁnal product quality. This article has demonstrated
the feasibility of using process analytical technologies to measure
paracetamol concentration (4–40% w/w) in printlets of diﬀerent geo-
metries, formulation types and excipients. The developed model was
validated according to current international standards, demonstrating
excellent linearity (R2= 0.996) and accuracy (RMSEP=0.63%). This
manuscript reports for the ﬁrst time the development of a rapid, non-
destructive quality control method for 3D printed dosage forms, pro-
viding a transformative approach to support the integration of 3DP into
clinical pharmacy practice.
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